Day: February 1, 2024

MRO Software Market Size Worth USD 11.36 Billion in 2032 | Emergen Research

Written by Customer Service on February 1, 2024. Posted in Mergers And Acquisitions.

Rising adoption of predictive and proactive maintenance services is a major factor driving Maintenance, Repair, and Operations (MRO) market revenue growth Vancouver, Feb. 01, 2024 (GLOBE NEWSWIRE) — The global Maintenance, Repair, and Operations (MRO) software market size was USD 7.03 Billion in 2022 and is expected to register a revenue CAGR of 5.0% during the forecast period. The steady market revenue growth can be attributed to increase in flight travels and air traffic, rising demand for advanced MROs and reduced turnaround time, growing adoption of software as service, increase in maintenance, repair and overhaul services of aircraft, and increase in technological advancements in software used in aviation industry. MRO software tracks and streamlines the tasks involved in maintaining, repairing, or rebuilding machinery. Moreover,...

Standard Uranium Announces Acquisition of Three Additional Uranium Exploration Properties in the Athabasca Basin Region, Saskatchewan

Written by Customer Service on February 1, 2024. Posted in Mergers And Acquisitions.

Figure 1.Overview map of Standard Uranium’s ten AthabascaFigure 2.Plan map highlighting the Cable Bay shear zone and EM conductor trends on the Cable Bay SW project along strike from anomalous uranium samples, with first vertical derivative magnetics in the background.Figure 3.Plan map highlighting the magnetic low/EM corridor at Ox Lake crosscut by an interpreted N-S trending regional fault, in addition to spatial relationships to uranium occurrences. First vertical derivative magnetics in the background.Figure 4.Plan map highlighting the magnetic low/fault trend on the Brown Lake project along strike from the high-grade Shift Lake Uranium Zone, with background first vertical derivative magnetics.VANCOUVER, British Columbia, Feb. 01, 2024 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard...

FirstCash Reports Fourth Quarter and Full-Year Operating Results; Record Pawn Receivables Drive Strong Revenue and Earnings Growth; Company Adds 157 Pawn Stores in 2023; Declares Quarterly Cash Dividend

Written by Customer Service on February 1, 2024. Posted in Dividend Reports And Estimates.

FORT WORTH, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) — FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), the leading international operator of almost 3,000 retail pawn stores and a leading provider of retail point-of-sale (“POS”) payment solutions through American First Finance (“AFF”), today announced operating results for the fourth quarter and full-year ended December 31, 2023. The Company also announced that the Board of Directors declared a quarterly cash dividend of $0.35 per share, which will be paid in February 2024. Mr. Rick Wessel, chief executive officer, stated, “FirstCash posted impressive fourth quarter and full year results for 2023 with continued momentum from record pawn receivables and new store growth resulting in strong year-over-year increases in revenues and earnings. U.S. pawn receivables...

Nxu Provides Business Update Following 2023 Fiscal Year End

Written by Customer Service on February 1, 2024. Posted in Public Companies.

Nxu generates revenue for second consecutive quarter, debuts production charging unit, regains Nasdaq compliance and pursues critical highway charging locations within NEVI corridors MESA, Ariz., Feb. 01, 2024 (GLOBE NEWSWIRE) — Nxu Inc. (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company developing and manufacturing innovative EV charging and energy storage solutions for the infrastructure we need to power our electrified future, achieved several important milestones in Q4 2023, continuing the innovation that advances its vision of making electric mobility viable:Revenue and Product Production: The Company generated quarter-over-quarter revenue growth in Q4 2023, the second consecutive quarter of revenue. Revenue growth was primarily comprised from the delivery of electric vehicle battery components, though Nxu...

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Written by Customer Service on February 1, 2024. Posted in Public Companies.

BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 30 days following the presentation. About Verve Therapeutics Verve Therapeutics, Inc. is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic...

Brunswick Corporation Releases 2023 Fourth Quarter & Full Year Earnings

Written by Customer Service on February 1, 2024. Posted in Public Companies.

METTAWA, Ill., Feb. 01, 2024 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), today, released its fourth quarter and full year 2023 financial results. A complete and full-text financial results press release is available on the Company’s website at https://ir.brunswick.com. The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1. The Company will hold a conference call at 10 a.m. CST/ 11 a.m. EST, today, Thursday, February 1, 2024, hosted by David M. Foulkes, chief executive officer, Ryan M. Gwillim, executive vice president and chief financial officer and Neha Clark, senior vice president, enterprise finance. A copy of the presentation to be used on this call will be available when the results are released as noted above. Security analysts and investors wishing...

Record 2023 Results Strengthen the Foundation for Continuous Growth

Written by Customer Service on February 1, 2024. Posted in Public Companies.

Record 2023 Results Strengthen the Foundation for Continuous GrowthNet revenues of Euro 5,970 million, up 17.2% versus prior year, with total shipments of 13,663 units up 3.3% versus FY 2022 Adjusted EBIT(1) of Euro 1,617 million, up 31.8% versus prior year, with adjusted EBIT(1) margin of 27.1% Adjusted net profit(1) of Euro 1,257 million and adjusted diluted EPS(1) at Euro 6.90 Adjusted EBITDA(1) of Euro 2,279 million, up 28.5% versus prior year, with adjusted EBITDA(1) margin of 38.2% Industrial free cash flow(1) generation of Euro 932 million“2023 was a very successful year, during which we strengthened our brand through a number of achievements reflected in our unprecedented financial results. For the first time, our net profit, up 34%, exceeded 1 billion Euro and the annual EBITDA margin rose to 38.2%,” said Benedetto Vigna,...

Oaktree Specialty Lending Corporation Announces First Fiscal Quarter 2024 Financial Results and Declares Quarterly Distribution of $0.55 Per Share

Written by Customer Service on February 1, 2024. Posted in Public Companies.

LOS ANGELES, Feb. 01, 2024 (GLOBE NEWSWIRE) — Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“Oaktree Specialty Lending” or the “Company”), a specialty finance company, today announced its financial results for the fiscal quarter ended December 31, 2023. Financial Highlights for the Quarter Ended December 31, 2023Total investment income was $98.0 million ($1.26 per share) for the first fiscal quarter of 2024, as compared with $101.9 million ($1.32 per share) for the fourth fiscal quarter of 2023. Adjusted total investment income was $98.0 million ($1.26 per share) for the first fiscal quarter, as compared with $102.2 million ($1.32 per share) for the fourth fiscal quarter of 2023. The decrease for the quarter was primarily driven by lower interest income, mainly due to an increase in non-accrual investments, partially...

Coherent Introduces ExactWeld 410 Laser Welding System for Medical Device Manufacturing

Written by Customer Service on February 1, 2024. Posted in Public Companies.

Coherent will showcase its full suite of medical device manufacturing systems at MDM West, at the Anaheim Convention Center in California, Feb. 6-8.Coherent’s ExactWeld 410 system for precision welding of medical devicesThe ExactWeld 410 from Coherent is a new system that excels at the most demanding requirements for precision welding of medical devices. The system is built for optimal cost of ownership with a small footprint that fits into production lines when floor space is a premium, supports a broad range of application and production needs, and provides traceability of process quality.PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a leader in industrial lasers for precision manufacturing, today introduced the ExactWeld 410 laser welding system for medical device manufacturing.Medical...

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Written by Customer Service on February 1, 2024. Posted in Public Companies.

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The FDA stated in the public communication that it is aware that some providers may be preparing other sodium thiosulfate (STS) products for patient use in...

Day: February 1, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals